Full-Life Technologies Acquires Focus-X Therapeutics

Full-Life Technologies, a radiotherapeutics company, has entered into an agreement to acquire Focus-X Therapeutics and its cancer-targeting radiopharmaceuticals.

Under the terms of the acquisition, Full-Life will gain Focus-X’s two investigational lead compounds. The first is a prostate specific membrane antigen-targeted peptide for the treatment of metastatic castration resistant prostate cancer. The second is a neurotensin receptor type 1 (NTSR1)-targeted peptide for the treatment of pancreatic cancer. 

Full-Life will also be acquiring Focus-X’s six other programs that are in earlier stages of development.

Under the terms of the acquisition, Focus-X shareholders are eligible to receive an upfront payment along with potential development, regulatory and sales-based milestone payments of up to $245 million. The acquisition is expected to close in the first quarter of 2023.